NYSE:DPLO

Diplomat Pharmacy (DPLO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.00
$4.01
50-Day Range
$4.00
$4.00
52-Week Range
$2.43
$14.46
Volume
744,968 shs
Average Volume
545,194 shs
Market Capitalization
$304 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DPLO stock logo

About Diplomat Pharmacy Stock (NYSE:DPLO)

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

DPLO Stock News Headlines

World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Diplomat Cocktail
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
See More Headlines
Receive DPLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diplomat Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
4/25/2024

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Fax
N/A
Employees
2,335
Year Founded
N/A

Profitability

Net Income
$-302,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.49 billion
Cash Flow
$4.60 per share
Book Value
$6.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$304 million
Optionable
Optionable
Beta
0.82
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Brian Thomas Griffin (Age 60)
    CEO & Chairman
  • Mr. Philip R. Hagerman (Age 67)
    Co-Founder & Chairman Emeritus
  • Mr. Daniel Paul Davison
    CFO & Treasurer
  • Mr. Dave Loschinskey (Age 48)
    Chief Operating Officer
  • Ms. Terri Anne Powers
    VP of Investor Relations

DPLO Stock Analysis - Frequently Asked Questions

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) issued its earnings results on Tuesday, November, 12th. The company reported ($2.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $2.15. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a negative trailing twelve-month return on equity of 12.15% and a negative net margin of 12.47%. The company's revenue was down 5.3% compared to the same quarter last year.

What other stocks do shareholders of Diplomat Pharmacy own?
This page (NYSE:DPLO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners